Related Experiment Video
Updated: Sep 16, 2025
Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
Published on: April 19, 2024
Antimicrobial resistance in chronic lung infection: the road to resistance
Wang Chun Kwok1, Katharine Pates2, Anand Shah3,4
1Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, Hong Kong.
Background:
Antimicrobial resistance (AMR) is a growing global health crisis and is particularly relevant to people living with chronic lung diseases such as bronchiectasis, cystic fibrosis and chronic obstructive pulmonary disease. These conditions frequently involve acute and chronic bacterial infections, requiring increased antibiotic usage and risk of AMR. Understanding the dynamics of AMR and emerging diagnostic and therapeutic strategies is crucial for optimising patient outcomes in this setting.
Aims:
This review explores the interplay between AMR and chronic bacterial lung infections, examining current understanding of pathogen epidemiology, diagnostic strategies, clinical implications of resistance and the impact of treatments. Future directions in research and therapeutic innovation are also outlined.
Narrative:
Key pathogens in chronic lung infections, such as Pseudomonas aeruginosa, Haemophilus influenzae, Staphylococcus aureus and Moraxella catarrhalis, exhibit diverse resistance mechanisms and AMR is linked to increased disease severity, exacerbation frequency and mortality, particularly with multidrug-resistant strains. Long-term antibiotic therapies, such as macrolides and inhaled agents, improve clinical outcomes but may drive resistance, necessitating ongoing efforts to understand how they can best be employed. Traditional diagnostic methods, such as culture-based antimicrobial susceptibility testing, often fail to capture the complexity of polymicrobial infections and resistomes. Although advanced techniques like next-generation sequencing and metagenomics are able to identify clinically relevant resistotypes, their development toward clinical utility is still in progress.
Conclusions:
AMR in chronic lung infections represents a dynamic and multifaceted challenge. Novel antibiotics, precision medicine approaches and alternative therapies such as bacteriophages show promise but require further validation. Improved stewardship and individualised treatment strategies are critical for mitigating AMR and enhancing patient outcomes. Collaborative efforts among researchers, clinicians and policy-makers are vital to advancing care and combating this global threat.
Insights
Antimicrobial resistance (AMR) in chronic lung infections is a major health threat. New treatments and better antibiotic stewardship are needed to combat drug-resistant bacteria and improve patient outcomes.
Area of Science:
- Medical Microbiology
- Infectious Diseases
- Pulmonary Medicine
Background:
- Antimicrobial resistance (AMR) poses a significant global health challenge, especially for individuals with chronic lung diseases like bronchiectasis, cystic fibrosis, and COPD.
- These conditions often involve recurrent bacterial infections, leading to increased antibiotic use and a higher risk of developing AMR.
Purpose of the Study:
- This review examines the complex relationship between AMR and chronic bacterial lung infections.
- It covers pathogen epidemiology, diagnostic methods, clinical impacts of resistance, and treatment effects, outlining future research and therapeutic directions.
Main Methods:
- Literature review of current understanding on AMR in chronic lung infections.
- Analysis of pathogen resistance mechanisms, diagnostic techniques, and therapeutic strategies.
Main Results:
- Key pathogens like Pseudomonas aeruginosa and Staphylococcus aureus show diverse resistance mechanisms, with AMR linked to increased disease severity and mortality.
- Long-term antibiotic therapies can improve outcomes but may contribute to resistance, requiring careful management.
- Traditional diagnostics struggle with polymicrobial infections; advanced methods like sequencing show promise but need further clinical development.
Conclusions:
- AMR in chronic lung infections is a complex, evolving problem requiring novel solutions.
- Emerging therapies like bacteriophages and precision medicine offer potential but need validation.
- Enhanced stewardship and personalized treatments are crucial for mitigating AMR and improving patient care.
Related Concept Videos
01:30Development of Antibiotic Resistance
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:22Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:31Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...